Apothecary Pharma Recalls 22 Compounded Tirzepatide Vials Over Sterility Assurance
Apothecary Pharma voluntarily recalled 22 vials of compounded tirzepatide and one NAD+ vial nationwide over a lack of sterility assurance; the FDA classified both as Class II.